Citigroup Boosts Humana (NYSE:HUM) Price Target to $350.00

Humana (NYSE:HUM) had its target price upped by Citigroup from $340.00 to $350.00 in a research report report published on Thursday morning, Stock Target Advisor reports. They currently have a buy rating on the insurance provider’s stock.

HUM has been the topic of a number of other reports. JPMorgan Chase & Co. upped their price objective on Humana from $288.00 to $322.00 and gave the company an overweight rating in a report on Thursday, August 1st. Morgan Stanley reduced their target price on Humana from $342.00 to $337.00 and set an overweight rating on the stock in a report on Thursday, September 26th. Cantor Fitzgerald raised Humana from a neutral rating to an overweight rating and increased their target price for the stock from $300.00 to $345.00 in a report on Monday, August 12th. Deutsche Bank began coverage on Humana in a report on Thursday, September 12th. They set a hold rating and a $300.00 target price on the stock. Finally, BMO Capital Markets lowered Humana from an outperform rating to a market perform rating and reduced their target price for the stock from $345.00 to $290.00 in a report on Monday, September 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $322.63.

NYSE HUM traded up $2.44 during trading on Thursday, hitting $317.58. The stock had a trading volume of 1,173,375 shares, compared to its average volume of 1,220,728. The company has a market capitalization of $39.82 billion, a PE ratio of 21.83, a P/E/G ratio of 1.27 and a beta of 0.85. The company’s 50-day moving average price is $277.48 and its two-hundred day moving average price is $270.93. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75. Humana has a 12 month low of $225.65 and a 12 month high of $342.03.

Humana (NYSE:HUM) last released its earnings results on Wednesday, November 6th. The insurance provider reported $5.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.58 by $0.45. The firm had revenue of $16.24 billion for the quarter, compared to analysts’ expectations of $16.15 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.58 EPS. As a group, equities analysts anticipate that Humana will post 17.75 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend is Monday, December 30th. Humana’s dividend payout ratio (DPR) is currently 15.12%.

In other news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the sale, the insider now directly owns 12,994 shares of the company’s stock, valued at approximately $3,764,361.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.54% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Whittier Trust Co. bought a new stake in shares of Humana during the 2nd quarter worth $27,000. Next Capital Management LLC acquired a new stake in shares of Humana in the second quarter valued at about $27,000. Endurance Wealth Management Inc. increased its stake in shares of Humana by 354.5% in the third quarter. Endurance Wealth Management Inc. now owns 100 shares of the insurance provider’s stock valued at $26,000 after buying an additional 78 shares during the period. Quest Capital Management Inc. ADV acquired a new stake in shares of Humana in the third quarter valued at about $30,000. Finally, Advantage Investment Management LLC increased its stake in shares of Humana by 287.1% in the second quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock valued at $32,000 after buying an additional 89 shares during the period. Institutional investors and hedge funds own 92.93% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Story: What is the CBOE Russell 2000® Volatility Index?

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.